Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Foerster

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
European Journal of Internal Medicine|June 4, 2018
Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCCFriedrich Foerster, Jens Mittler, Felix Darstein, et al.
Clinical and Translational Gastroenterology|September 10, 2022
13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial ChemoembolizationSimon Johannes Gairing, Robert Kuchen, Lukas Müller, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2026
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma-Data From the Multinational LITCHI RegistryUlrike Bauer, Maria R Troppmair, Najib Ben Khaled, et al.
JHEP Reports : Innovation in Hepatology|April 30, 2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCCNajib Ben Khaled, Raphael Mohr, Leonie S Jochheim, et al.
Nature|February 11, 2011
Telomere dysfunction induces metabolic and mitochondrial compromiseErgün Sahin, Simona Colla, Marc Liesa, et al.
JHEP Reports : Innovation in Hepatology|February 4, 2026
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunityIgnazio Piseddu, Leonie S Jochheim, Katrin Boettcher, et al.
Therapeutic Advances in Medical Oncology|February 24, 2026
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)Najib Ben Khaled, Ursula Ehmer, Ilja Kubisch, et al.
Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
European Journal of Internal Medicine|June 4, 2018
Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCCFriedrich Foerster, Jens Mittler, Felix Darstein, et al.
Clinical and Translational Gastroenterology|September 10, 2022
13 C-Methacetin Breath Test Predicts Survival in Patients With Hepatocellular Carcinoma Undergoing Transarterial ChemoembolizationSimon Johannes Gairing, Robert Kuchen, Lukas Müller, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2026
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma-Data From the Multinational LITCHI RegistryUlrike Bauer, Maria R Troppmair, Najib Ben Khaled, et al.
JHEP Reports : Innovation in Hepatology|April 30, 2026
Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCCNajib Ben Khaled, Raphael Mohr, Leonie S Jochheim, et al.
Nature|February 11, 2011
Telomere dysfunction induces metabolic and mitochondrial compromiseErgün Sahin, Simona Colla, Marc Liesa, et al.
JHEP Reports : Innovation in Hepatology|February 4, 2026
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunityIgnazio Piseddu, Leonie S Jochheim, Katrin Boettcher, et al.
Therapeutic Advances in Medical Oncology|February 24, 2026
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)Najib Ben Khaled, Ursula Ehmer, Ilja Kubisch, et al.
Journal of Hepatology|December 21, 2024
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinomaSarah Cappuyns, Marta Piqué-Gili, Roger Esteban-Fabró, et al.
JHEP Reports : Innovation in Hepatology|March 10, 2025
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumabSimon Johannes Gairing, Philipp Mildenberger, Jennifer Gile, et al.
Nature|December 11, 2024
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumoursIgnacio Melero, Maria de Miguel Luken, Guillermo de Velasco, et al.
Pageof 6